(Reuters) – Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder.
(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Agios’ blood disorder drug meets goals of late-stage study
Jan 3, 2024 | 5:42 AM
